All In MedTech

FDA Clearance Tracker · P050038

ARISTA AH ABSORBABLE HEMOSTAT

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Sep 26, 2006 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Sep 26, 2006

Approved

Time to decision

361 days

Received Sep 30, 2005. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P050038
Device name
ARISTA AH ABSORBABLE HEMOSTAT
Applicant
Davol, Inc.
Applicant location
Warwick, RI
Received
Sep 30, 2005
Decided
Sep 26, 2006
Decision
Approved
Supplements
40 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code LMG

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE ARISTA AH ABSORBABLE HEMOSTAT. THE DEVICE IS INDICATED FOR USE IN SURGICAL PROCEDURES (EXCEPT NEUROLOGICAL, OPHTHALMIC, AND UROLOGICAL) AS AN ADJUNCTIVE HEMOSTATIC DEVICE TO ASSIST WHEN CONTROL OF CAPILLARY, VENOUS, AND ARTERIOLAR BLEEDING BY PRESSURE, LIGATURE AND OTHER CONVENTIONAL PROCEDURES IS INEFFECTIVE OR IMPRACTICAL.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LMG. The earliest in FDA's data is N12159, decided Oct 14, 1960.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Davol, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.